RxDoctor Payments Data

Lee Haas

Nurse Practitioner · Louisville, KYNPI 1598113433

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $67,992 of the $95,092 with a category attached, or 71.5%. Lilly USA, LLC accounts for 75.7% of it on its own, with 27 other manufacturers making up the rest. Among nurse practitioner clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$95,092in general payments, 2019–2025

Across 807 payments — averaging $117.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$72K
  • E.r. Squibb & Sons, L.L.C.$6K
  • UCB, Inc.$4K
  • Eli Lilly$4K
  • AbbVie$2K
  • Johnson & Johnson$2K
  • plus $5K from 22 others

What the payments were for

  • Consulting fees$7,6588%
  • Speaking & faculty fees$67,99272%
  • Travel & lodging$6,0396%
  • Food & beverage$12,72313%
  • Education$6811%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$95,092 in reported general payments places this provider in the 95th percentile of 1,918 nurse practitioner providers in Kentucky.

See all nurse practitioner providers in Kentucky

Medicare billing

Part B allowed, 2024
$104,250
Medicare patients
553
Services billed
2,554

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab33$122,371
OtezlaApremilast19$88,494
RinvoqUpadacitinib12$72,620
Clobetasol Propionate64$2,997
Fluorouracil29$2,029
Ketoconazole128$1,954
Metronidazole36$1,953
Doxycycline Hyclate60$1,663
Triamcinolone Acetonide118$1,044
Tretinoin17$965
ValacyclovirValacyclovir Hcl20$751
Desonide22$745
Clindamycin Phosphate21$696
Betamethasone Dipropionate14$467
Hydrocortisone77$433

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$226$88,49419 claims
AbbVieRinvoq$2,389$72,62012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,918 nurse practitioner providers in Kentucky.

Other nurse practitioner in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →